Parenteral anticoagulation in ambulatory patients with cancer (Q22252972)

7 February 2023

4

Maddalena Barba

Maddalena

Barba

1 reference

7 February 2023

7

Saskia Middeldorp

Saskia

Middeldorp

1 reference

7 February 2023

1

Elie A Akl

Elie A

Akl

1 reference

7 February 2023

2

Lara A

Kahale

Lara A Kahale

1 reference

7 February 2023

5

Victor E D

Yosuico

Victor E D Yosuico

1 reference

25491949

7 February 2023

Frederiek F van Doormaal

6

Frederiek F

van Doormaal

Frederiek F van Doormaal

1 reference

7 February 2023

3

Rami A

Ballout

Rami A Ballout

1 reference

7 February 2023

Andrew Bryant

8

Andrew

Bryant

1 reference

25491949

Cochrane Database of Systematic Reviews

7 February 2023

language of work or name

English

0 references

publication date

10 December 2014

0 references

published in

0 references

issue

12

0 references

page(s)

CD006652

0 references

cites work

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Low-molecular-weight heparin and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy--report of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Do low-molecular-weight heparins improve the survival of cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Increasing the efficiency of cancer chemotherapy with heparin: "clinical study".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Heparin and chemotherapy in the management of inoperable lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Does low-molecular-weight heparin influence cancer-related mortality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Low molecular weight heparins could be important in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Anticoagulants in the treatment of small cell carcinoma of the bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Heparin-induced thrombocytopenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Can low-molecular-weight heparins improve outcome in patients with cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Heparin treatment of malignancy: the case for clinical trials in colon cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Low dose intravesical heparin as prophylaxis against recurrent noninvasive (stage Ta) bladder cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Heparin and cancer revisited

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Hemostasis and malignancy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Lack of effect of coumarin in women with lymphedema after treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Antidepressants for old people. Research on antidepressants in the elderly population is scarce

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

[Risk and prevention of thromboembolism complications in gynecologic malignancies]

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Heparin for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

Antithrombotic therapy in cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006652.PUB4

7 January 2021

10.1002/14651858.CD006652.PUB4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

25491949

1 reference

Consolidated OpenCitations Corpus – April 2017